Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Luca Richeldi, Kerri A Johannson, Irina Strâmbu, Claudia Ravaglia, Jan C Grutters, Claudia Valenzuela, Nesrin Mogulkoc, Fabrizio Luppi, Athol U Wells, Carlo Vancheri, Michael Kreuter, Carlo Albera, Katerina M. Antoniou, Goksel Altinisik, Elisabeth Bendstrup, Benjamin Bondue, Raphael Borie, Kevin K. Brown, Philippe Camus, Diego CastilloHarold R. Collard, Vincent Cottin, Nunzio Crimi, Giovanni Ferrara, Aryeh Fischer, Jack Gauldie, Thomas Geiser, Andreas Guenther, Nathan Hambly, David M. Hansell, Sergio Harari, Mark G. Jones, Michael Keane, Brett Ley, Toby M. Maher, Maria Molina-Molina, Stefano Palmucci, Venerino Poletti, Antje Prasse, Paola Rottoli, Paolo Spagnolo, Martina Sterclova, Sebastiano Torrisi, Eliza Tsitoura, Martina Vasakova, Simon L. Walsh, Marlies S. Wijsenbeek, Wim A. Wuyts

Research output: Contribution to journalArticle

43 Citations (Scopus)


Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.
Original languageEnglish
Pages (from-to)591-598
Number of pages8
JournalThe Lancet Respiratory Medicine
Publication statusPublished - 2017


  • Antacids
  • Disease Progression
  • Gastroesophageal Reflux
  • Histamine H2 Antagonists
  • Humans
  • Idiopathic Pulmonary Fibrosis
  • Practice Guidelines as Topic
  • Proton Pump Inhibitors
  • Pulmonary and Respiratory Medicine
  • Risk Factors
  • Severity of Illness Index


Dive into the research topics of 'Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?'. Together they form a unique fingerprint.

Cite this